A simple method has been developed for the estimation of triclabendazole and ivermectin in a pharmaceutical suspension dosage form present in 50:1 ratio respectively, by reversed-phase High-Performance Liquid Chromatography (HPLC). The isocratic LC analysis was performed on Vydac, C-18, (250 X 4.6 mm, 5 µ) using mobile phase comprising of acetonitrile, methanol and water at a flow rate of 1.5 ml/minute. Quantification was carried out by using UV detector at 254 nm and the run time was 15 minutes. Linearity was found to be 0.06-0.14 and 0.03-0.05 mg/ml with a correlation co-efficient, r= 0.998 and 0.999 for triclabendazole and ivermectin respectively. The percentage recovery values were found to be within the range of 98-102. The analytical method has been successively applied to pharmaceutical formulation and was validated according to International Conference on Harmonization (ICH) guidelines.
Introduction
Triclabendazole (TCBZ) has been the drug of choice to treat liver fluke infections in livestock for more than 20 years, due to its high activity against both adult and juvenile flukes. TCBZ is a benzimidazole derivative and, by analogy with what is known about other benzimidazole drugs, it would be anticipated that TCBZ might bind to the β-tubulin molecule and so disrupt microtubule-based processes 1 . On the other hand ivermectin (IVR) has potent activity at GABA receptors in both invertebrates and mammals, and GABA is known to be the primary inhibitory neurotransmitter in the nematode somatic neuromuscular system. However, subsequent work by Merck scientists identified glutamate-gated Cl¯ channels as the more likely physiological targets of ivermectin and related drugs 2 . Substantial in-vivo trials have been conducted to prove the effectiveness of this combination as flukicidal [3] [4] [5] . Three fold higher plasma availability of ivermectin was reported when co-administered with TCBZ. Similarly, Influential higher plasma concentrations of TCBZ and its metabolites were also reported on co-administration with IVR 6 . Keeping the high plasma availability of IVR in combination with TCBZ as key factor, a pharmaceutical suspension dosage form was prepared with TCBZ and IVR as 
Materials and Methods

Apparatus
Shimadzu HPLC equipped with quaternary pump, PDA detector and auto sampler, Agilent HPLC of 1100 series equipped with multi wavelength detector and manual injection port, 20 µl glass syringe, Vydac, C-18, (250 X 4.6 mm, 5 µ) column is used. Shimadzu Libror AEG-220 electronic balance is used for weighing the materials.
Chemicals and reagents
Triclabendazole and ivermectin were procured from Sigma Aldrich. Acetonitrile (HPLC grade), methanol (HPLC grade), propylene glycol (AR grade) and HPLC grade water prepared from Millipore water purification system were used for the study. Membrane filters (nylon 0.45 micron) and syringe filters (Hydrophilic PVDF, 0.45 micron) were purchased from Millipore (India) Pvt. Ltd., Bangalore.
Preparation of Standard solutions
Standard stock solutions of pure drugs were prepared separately in methanol containing 2 mg/ml of triclabendazole and 0.1 mg/ml of ivermectin and filtered through a 0.45 micron membrane filter. Preparation of Calibration Curve Triclabendazole For preparation of the calibration curve of TCBZ, aliquots 0.3, 0.4, 0.5, 0.6 and 0.7 ml of the standard stock solution of TCBZ (2 mg/ml) were transferred to a series of 10 ml volumetric flasks and the volume was made up to the mark with methanol. Ivermectin For preparation of the calibration curve of IVR, aliquots 1.5,1.75, 2.0, 2.25 and 2.5 ml of the standard stock solution of IVR (0.1 mg/ml) were transferred to a series of 5 ml volumetric flasks and the volume was made up to the mark with methanol. Analysis of suspension dosage form Preparation of sample solutions (Triclabendazole) An accurately weighed quantity of suspension equivalent to 50 mg of TCBZ was dissolved in 10 ml of methanol and sonicated for 5 minutes. The solution was filtered through Whatmann filter paper no.41.The residue was washed with 5 ml portions of methanol twice and the combined filtrate was made up to 25 ml with methanol (2mg/ml). Further, 0.5 ml of the above solution was made up to 10 ml with methanol (0.1mg/ml). The solution was then filtered through 0.45 µ syringe filter and analyzed by RP-HPLC.
Preparation of sample solutions (Ivermectin)
An accurately weighed quantity of suspension equivalent to 2.5 mg of IVR was transferred into 25 ml volumetric flask and dissolved in 2.5 ml of propylene glycol and sonicated for 5 minutes. The solution was made up to the mark with water and sonicated for 10 minutes. The above solution was centrifuged for 5 minutes at around 5000 RPM. 2 ml of the supernatant was taken into a 5ml volumetric flask and the final concentration was brought to 0.04 mg/ml with methanol. The solution was then filtered through 0.45 µ syringe filter and analyzed by RP-HPLC.
Results and Discussion
Method development
It was challenging to develop a method for simultaneous estimation of TCBZ and IVR as they are present in the ratio of 50:1 in the formulation. In order to overcome the huge differences occurred in the peak heights due to the concentration of TCBZ and IVR in the formulation, a selective sample preparation method is developed for IVR. Mobile phase containing Acetonitrile: Methanol: Water in the ratio of 60:30:10 at a flow rate of 1.5 ml/minute were selected as it was found ideal to resolve TCBZ and IVR. HPLC conditions were mentioned in Table  No. 1. System suitability System suitability studies were carried out on a freshly prepared solution of standards and the results are tabulated in Table No. 2. Analytical method validation Specificity Spiked a known quantity of working standard into placebo and analyzed using PDA detector. No interfering peaks observed at the retention time of TCBZ and IVR. Percentage recovery of TCBZ and IVR spiked quantity was found to be in the range of 98-102%. Precision Precision of the method was tested by six repeated injections of standard and sample solutions and measuring the peak areas and calculated the percentage assay. Intermediate precision was established by performing the analysis of the formulation in replicates by different analyst and reproducibility, using two different instruments in different labs. The results were found to be satisfactory as the RSD values were found to be less than 2%. The results of repeatability, intermediate precision and reproducibility were tabulated in Table  No. 3. Accuracy To check the accuracy of the developed methods and to study the interference of formulation additives, analytical recovery experiments were carried out by standard addition method at three different levels. From the total amount of drug found, the percentage recovery was calculated and the results were found to be within the acceptable limit of 98-102%. The results were reported in Table No . 4 . Robustness The robustness of a method is its ability to remain unaffected by small deliberate variations in the method parameters. Robustness of the method was checked by making slight changes in the composition of mobile phase and by changing the column temperature. The results were found to be within the specified limits for triclabendazole (4.62 -5.37 %W/V) and ivermectin (0.092 -0.107 %W/V). The results were reported in Table No . 5.
Conclusion
The validated RP-HPLC method employed here proved to be simple, fast, accurate, precise and sensitive enough. Selectivity experiment showed that there is no interference or overlapping of the peaks either due to diluents with the main peak of TCBZ and IVR. The percentage RSD for precision is <2 which confirms that method is sufficiently precise. The proposed method is simple, fast, accurate, and precise and can be used for routine analysis in quality control of TCBZ and IVR in pharmaceutical suspension dosage form.
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